Clinical Versus Pathologic Staging in Early-Stage Non-Small Cell Lung Cancer Assessed by an Established Lung Cancer Multidisciplinary Meeting - PubMed
3 hours ago
- #Multidisciplinary Team
- #Non-Small Cell Lung Cancer
- #Clinical Staging
- The study compares clinical and pathological staging in early-stage non-small cell lung cancer (NSCLC) assessed by a multidisciplinary team (MDT).
- Clinical and pathological staging concordance occurred in 73% of cases, with 18.9% clinically under-staged.
- Factors linked to clinical under-staging include time between CT imaging and surgery, and histopathologic evidence of visceral pleural, vessel, and lymphatic invasion.
- Clinically under-staged patients had a significantly higher risk of mortality (OR 2.06) and disease recurrence (OR 2.06).
- Discrepancies affecting treatment decisions occurred in 7% of patients.
- The study suggests that treatment delays and malignancy histopathological features contribute to staging disagreements.
- Improved timeliness of care could reduce under-staging risks, and staging concordance should be a routine benchmark for lung cancer MDTs.